Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zmax Clear all

Conditions: Covid-19
Interventions: HCQ, HCQ+AZT, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more

Conditions: Blepharitis
Interventions: AzaSite®; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Lynbrook, New York

Conditions: COVID-19
Interventions: Hydroxychloroquine, Azithromycin, Zinc Sulfate, Doxycycline; Drug
Lead sponsor: St. Francis Hospital, New York; Other
Eligibility: 30 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Roslyn, New York

Conditions: Pertussis
Interventions: Antibiotic PEP; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malaria Prophylaxis
Interventions: azithromycin (AZ) microsphere, test chloroquine (CQ) formulation, azithromycin (AZ), chloroquine (CQ); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV, Pregnancy Malaria, Sexually Transmitted Infection
Interventions: Azithromycin/TMPS, Placebo/TMPS; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 55 Years · Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COVID-19, SARS-CoV-2
Interventions: Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 6
States / cities: Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more

Conditions: Bacterial Infections, Eye Infections, Cataract Extraction
Interventions: AzaSite Eye Drops, Vigamox Eye Drops; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more

Conditions: Bacterial Infections, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Child Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 11 Months
Enrollment: 694,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Groton, Connecticut • Bethesda, Maryland

Conditions: Sinusitis
Interventions: Zithromax (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology, Blood sampling for plasma chemistry profile, Serum pregnancy test (for women of child-bearing potential); Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more

Conditions: Ureaplasma, Bacterial Infection
Interventions: Azithromycin; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 30 Days
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Detroit, Michigan • Cleveland, Ohio

Conditions: Mycobacterium Avium Complex
Interventions: Azithromycin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malaria
Interventions: Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®); Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Otitis Media
Interventions: Zmax; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 48 Months
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Bardstown, Kentucky • Springfield, Kentucky

Conditions: Childhood Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 60 Months
Enrollment: 66,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: PANS, PANDAS, Obsessive Compulsive Disorder (OCD)
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 14 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Blepharitis
Interventions: AzaSite®; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 9
States / cities: Artesia, California • Mission Hills, California • Miami, Florida + 5 more

Conditions: Healthy Volunteers
Interventions: SPR720, Azithromycin, Ethambutol; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Months
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin; Drug
Lead sponsor: Anderson Clinical Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Hampton, Virginia

Conditions: Healthy
Interventions: Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting

Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure

A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects

A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV

Treatment for COVID-19 in High-Risk Adult Outpatients

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

Infant Mortality Reduction by the Mass Administration of Azithromycin

A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates

A Study of Standard Drugs for Mycobacterium Avium Complex

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg